Iterum Therapeutics Plc (ITRM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Iterum Therapeutics Plc (ITRM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11045
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Iterum Therapeutics Plc (Iterum Therapeutics) is a clinical-stage pharmaceutical company which develops anti-infectives for multi-drug resistant (MDR) pathogens for treating serious and life-threatening diseases. The company is developing Sulopenem, an oral and IV targeted-spectrum penem antibiotic for the treatment of infections caused by multi-drug resistant, gram-negative bacteria in both the hospital and community environments. Iterum Therapeutics seeks to work in partnership with other pharmaceutical companies for product development and commercialization opportunities. The company has operations with research and development facility in the US. Iterum Therapeutics is headquartered in Dublin, Ireland.

Iterum Therapeutics Plc (ITRM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Iterum Therapeutics Raises Additional USD32.3 Million in Venture Financing 10
Iterum Therapeutics Raises USD65 Million in Series B Venture Financing 11
Iterum Therapeutics Raises Additional USD24 Million in Venture Financing 13
Iterum Therapeutics Raises USD40 Million in Series A Financing 14
Iterum Therapeutics Raises USD23.79 Million in Venture Financing 16
Licensing Agreements 17
Iterum Therapeutics Enters into Licensing Agreement with Pfizer 17
Equity Offering 18
Iterum Therapeutics Raises USD80 Million in IPO of Shares 18
Iterum Therapeutics Raises USD649 Million in Private Placement of Shares 20
Iterum Therapeutics Plc – Key Competitors 21
Iterum Therapeutics Plc – Key Employees 22
Iterum Therapeutics Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Nov 14, 2018: Iterum reports third quarter 2018 financial results 24
Aug 14, 2018: Iterum announces second quarter 2018 financial results 25
Corporate Communications 26
Feb 20, 2018: Iterum Therapeutics Appoints Jeff Schaffnit As Chief Commercial Officer 26
Product News 27
01/05/2017: Iterum Announces Sulopenem in Development for Treatment of Gram-Negative, Multi-drug Resistant Infections 27
Clinical Trials 28
Jul 25, 2017: Iterum Gains Important Support for Development of Novel Oral Antibiotic, Sulopenem 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iterum Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Iterum Therapeutics Raises Additional USD32.3 Million in Venture Financing 10
Iterum Therapeutics Raises USD65 Million in Series B Venture Financing 11
Iterum Therapeutics Raises Additional USD24 Million in Venture Financing 13
Iterum Therapeutics Raises USD40 Million in Series A Financing 14
Iterum Therapeutics Raises USD23.79 Million in Venture Financing 16
Iterum Therapeutics Enters into Licensing Agreement with Pfizer 17
Iterum Therapeutics Raises USD80 Million in IPO of Shares 18
Iterum Therapeutics Raises USD649 Million in Private Placement of Shares 20
Iterum Therapeutics Plc, Key Competitors 21
Iterum Therapeutics Plc, Key Employees 22
Iterum Therapeutics Plc, Other Locations 23

List of Figures
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iterum Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Iterum Therapeutics Plc (ITRM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TAT Technologies, Ltd.:企業の戦略・SWOT・財務分析
    TAT Technologies, Ltd. - Strategy, SWOT and Corporate Finance Report Summary TAT Technologies, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Passenger Rail Agency of South Africa:企業の戦略的SWOT分析
    Passenger Rail Agency of South Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Adams Rite Aerospace, Inc.:企業の戦略・SWOT・財務情報
    Adams Rite Aerospace, Inc. - Strategy, SWOT and Corporate Finance Report Summary Adams Rite Aerospace, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Takeda Pharmaceuticals International AG-製薬・医療分野:企業M&A・提携分析
    Summary Takeda Pharmaceuticals International AG (Takeda), a subsidiary of Takeda Pharmaceutical Company Ltd is a developer, manufacturer and distributor of pharmaceutical products. The company offers treatments in respiratory and immunology, central nervous system, cardiovascular and metabolic, canc …
  • Avista Corporation (AVA):電力:M&Aディール及び事業提携情報
    Summary Avista Corporation (Avista) is an electric and natural gas utility. The company produces, transmits, and distributes electricity; and supplies natural gas on retail and wholesale basis. It sources electricity from its facilities and contracted hydroelectric, thermal and wind generation facil …
  • Christus Health:企業の戦略的SWOT分析
    Christus Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Campofrio Food Group, S.A.:戦略・SWOT・企業財務分析
    Campofrio Food Group, S.A. - Strategy, SWOT and Corporate Finance Report Summary Campofrio Food Group, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • McDonald’s Australia Limited:企業の戦略的SWOT分析
    McDonald's Australia Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Drugs for Neglected Diseases initiative:製薬・医療:M&Aディール及び事業提携情報
    Summary Drugs for Neglected Diseases initiative (DNDi) is a non-profit drug research and development (R&D) organization which discovers and develops new drugs for neglected diseases. The organization develops therapeutics for the treatment of various diseases such as human African trypanosomiasis (H …
  • Animal Health International Inc:企業の戦略的SWOT分析
    Animal Health International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Laboratorios LETI SL:企業の戦略的SWOT分析
    Laboratorios LETI SL - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Mecklenburg Electric Cooperative:企業の戦略的SWOT分析
    Mecklenburg Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • GAIL (India) Ltd (GAIL)-石油・ガス分野:企業M&A・提携分析
    Summary GAIL (India) Ltd (GAIL) is a vertically integrated gas company that carries out exploration and production, transmission of natural gas. It also has presence in petrochemical, liquid hydrocarbons and power and renewable sectors. GAIL is also a major LPG transmission company, besides managing …
  • bluebird bio Inc (BLUE):製薬・医療:M&Aディール及び事業提携情報
    Summary Bluebird Bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immuno …
  • Compagnie de Saint-Gobain:企業のM&A・事業提携・投資動向
    Compagnie de Saint-Gobain - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Compagnie de Saint-Gobain Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • ComfortDelGro Corporation Limited:戦略・SWOT・企業財務分析
    ComfortDelGro Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary ComfortDelGro Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Daegu Bank Ltd:企業の戦略・SWOT・財務分析
    Daegu Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Daegu Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Arcam AB:企業の戦略的SWOT分析
    Arcam AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Novanta Inc (NOVT)-医療機器分野:企業M&A・提携分析
    Summary Novanta Inc (Novanta), formerly GSI Group Inc. is a medical device company that manufactures and markets precision photonics, motion control components and subsystems. The company provides laser products, medical technologies, and precision motion products. It offers laser sources and beam d …
  • Aeglea BioTherapeutics Inc (AGLE):企業の財務・戦略的SWOT分析
    Summary Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company’s product pipeline comprises AEB1102, AEB …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆